Developer docs
API playgroundTry for free, no card

Search company profiles

Amplyx Pharmaceuticals

Full company profile

uuid0000zw3

Namestring
Amplyx Pharmaceuticals
Websiteurl
amplyx.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Amplyx Pharmaceuticals is a privately held clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Diego, California. The company develops innovative small-molecule therapies targeting debilitating and life-threatening fungal infections in patients with compromised immune systems, including those with cancer, transplant recipients, and other immunocompromised populations. Its core pipeline centers on novel antifungal agents — most prominently the fosmanogepix (APX001) class — designed to address invasive candidiasis, aspergillosis, and rare mold infections where resistance to existing therapies is growing and mortality remains high.

The business operates as a venture-backed R&D organization. Across nine disclosed financing rounds from 2008 through May 2020, Amplyx has raised approximately $198 million from a syndicate led by Sofinnova Investments, RiverVest, 3x5 Special Opportunity Fund, and including New Enterprise Associates, Arix Bioscience, Lundbeckfonden Ventures, BioMed Ventures, Pappas Capital, Generation Ventures, Adage Capital Management, Pfizer, Keiretsu Forum, and TCA Venture Group. The May 2020 round notably included Pfizer as a strategic investor, creating a credible channel-to-market pathway given Pfizer's hospital anti-infective infrastructure.

The company has 11–50 employees organized around clinical development, program management, and operations. Leadership is concentrated in experienced anti-infective developers, including President & CEO Mike Grey, COO Christopher LeMasters, and senior clinical/development officers Carlos Sattler, Kevin Holme, and Pamela Wedel. Amplyx has no marketed products, no disclosed revenue, and operates as a pre-commercial entity; revenue mechanics are entirely prospective and contingent on regulatory approval, with potential pathways including direct commercialization, partnership, or acquisition by a large pharmaceutical company.

Short descriptiontext

Amplyx Pharmaceuticals is a San Diego-based, clinical-stage biopharmaceutical company founded in 2006 that develops novel antifungal therapies for life-threatening infections in immunocompromised patients, backed by approximately $198 million in venture financing led by Sofinnova and including Pfizer as a strategic investor.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antifungal therapeutics, infectious disease drugs, clinical-stage biopharmaceuticals, immunocompromised patient therapies, life-threatening fungal infections
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Therapeutics
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amplyx Pharmaceuticals develops innovative small-molecule therapies for debilitating and life-threatening diseases, with a primary focus on treating invasive fungal infections in patients with compromised immune systems. The company operates as a clinical-stage biopharmaceutical firm advancing novel antifungal drug candidates through preclinical and clinical development.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Antifungal therapy pipeline (innovative therapies for immunocompromised patients)
CategoryAntifungal Therapeutics
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical company with an established anti-infective franchise (including antifungals and the source of Amplyx's expanded access connection). Acts as both an investor and a potential strategic acquirer; comparable as a broad incumbent in the anti-infective space.

TypeBroad incumbent
Description

Global pharmaceutical company with a leading antifungal franchise (Cresemba/isavuconazole) widely used in immunocompromised patients. Comparable as a large incumbent with overlapping anti-infective assets and relevant commercial reach.

TypeDirect peer
Description

Clinical-stage biotechnology company developing antifungal and antiviral therapies, including treatments for invasive fungal infections in immunocompromised patients. Directly comparable in indication focus, modality, and patient population.

TypeDirect peer
Description

Developer of antifungal therapies (ibrexafungerp) targeting serious and life-threatening fungal infections, including in immunocompromised patients. Comparable in therapeutic area, clinical-stage profile, and patient population.

TypeDirect peer
Description

Late-stage biopharmaceutical company developing novel therapies for invasive fungal infections, particularly in immunocompromised patients with limited treatment options. Direct antifungal-focused peer with similar unmet-need positioning.

TypeDirect peer
Description

Swiss biopharmaceutical company with a commercialized antifungal franchise (Cresemba) and a pipeline in serious bacterial and fungal infections. Comparable as a focused anti-infective specialist with both development and commercial-stage assets.

TypeDirect peer
Description

Commercial-stage anti-infective company with marketed antibiotics for serious and life-threatening infections. Comparable as a focused infectious disease company addressing hospitalized and immunocompromised patient populations.

TypeDirect peer
Description

Commercial-stage biopharmaceutical company developing and commercializing antibiotics for serious community-acquired infections. Comparable as an infectious disease-focused specialty company with similar development and commercialization dynamics.

9Nabriva Therapeutics
TypeDirect peer
Description

Biopharmaceutical company developing anti-infective agents for serious and difficult-to-treat infections. Comparable as a development-stage anti-infective specialist addressing similar hospital and immunocompromised patient use cases.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel antifungal agents using metalloenzyme inhibitors. Comparable as a development-stage antifungal specialist targeting invasive fungal infections.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amplyx Pharmaceuticals

Infectious Disease Therapeuticsamplyx.com

Amplyx Pharmaceuticals is a San Diego-based, clinical-stage biopharmaceutical company founded in 2006 that develops novel antifungal therapies for life-threatening infections in immunocompromised patients, backed by approximately $198 million in venture financing led by Sofinnova and including Pfizer as a strategic investor.

What Amplyx Pharmaceuticals does

Amplyx Pharmaceuticals is a privately held clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Diego, California. The company develops innovative small-molecule therapies targeting debilitating and life-threatening fungal infections in patients with compromised immune systems, including those with cancer, transplant recipients, and other immunocompromised populations. Its core pipeline centers on novel antifungal agents — most prominently the fosmanogepix (APX001) class — designed to address invasive candidiasis, aspergillosis, and rare mold infections where resistance to existing therapies is growing and mortality remains high.

The business operates as a venture-backed R&D organization. Across nine disclosed financing rounds from 2008 through May 2020, Amplyx has raised approximately $198 million from a syndicate led by Sofinnova Investments, RiverVest, 3x5 Special Opportunity Fund, and including New Enterprise Associates, Arix Bioscience, Lundbeckfonden Ventures, BioMed Ventures, Pappas Capital, Generation Ventures, Adage Capital Management, Pfizer, Keiretsu Forum, and TCA Venture Group. The May 2020 round notably included Pfizer as a strategic investor, creating a credible channel-to-market pathway given Pfizer's hospital anti-infective infrastructure.

The company has 11–50 employees organized around clinical development, program management, and operations. Leadership is concentrated in experienced anti-infective developers, including President & CEO Mike Grey, COO Christopher LeMasters, and senior clinical/development officers Carlos Sattler, Kevin Holme, and Pamela Wedel. Amplyx has no marketed products, no disclosed revenue, and operates as a pre-commercial entity; revenue mechanics are entirely prospective and contingent on regulatory approval, with potential pathways including direct commercialization, partnership, or acquisition by a large pharmaceutical company.

Amplyx Pharmaceuticals firmographics

Firmographics
Name
Amplyx Pharmaceuticals
Website
https://amplyx.com
Company type
Private
Founded year
2006
Headcount range
11–50 employees
Short description
Amplyx Pharmaceuticals is a San Diego-based, clinical-stage biopharmaceutical company founded in 2006 that develops novel antifungal therapies for life-threatening infections in immunocompromised patients, backed by approximately $198 million in venture financing led by Sofinnova and including Pfizer as a strategic investor.
Ownership category
akta.pro rank

Amplyx Pharmaceuticals industry classification

Industry
Product category
Infectious Disease Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals

Keywords

  • Antifungal therapeutics
  • Infectious disease drugs
  • Clinical-stage biopharmaceuticals
  • Immunocompromised patient therapies
  • Life-threatening fungal infections

Where Amplyx Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Amplyx Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Amplyx Pharmaceuticals product offering

Product offering

Core offering

Amplyx Pharmaceuticals develops innovative small-molecule therapies for debilitating and life-threatening diseases, with a primary focus on treating invasive fungal infections in patients with compromised immune systems. The company operates as a clinical-stage biopharmaceutical firm advancing novel antifungal drug candidates through preclinical and clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antifungal therapy pipeline (innovative therapies for immunocompromised patients)

Companies that use Amplyx Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Amplyx Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Amplyx Pharmaceuticals partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Amplyx Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Global pharmaceutical company with an established anti-infective franchise (including antifungals and the source of Amplyx's expanded access connection). Acts as both an investor and a potential strategic acquirer; comparable as a broad incumbent in the anti-infective space.
  • Astellas Pharma: Global pharmaceutical company with a leading antifungal franchise (Cresemba/isavuconazole) widely used in immunocompromised patients. Comparable as a large incumbent with overlapping anti-infective assets and relevant commercial reach.

Direct peers

  • Cidara Therapeutics: Clinical-stage biotechnology company developing antifungal and antiviral therapies, including treatments for invasive fungal infections in immunocompromised patients. Directly comparable in indication focus, modality, and patient population.
  • Scynexis: Developer of antifungal therapies (ibrexafungerp) targeting serious and life-threatening fungal infections, including in immunocompromised patients. Comparable in therapeutic area, clinical-stage profile, and patient population.
  • F2G: Late-stage biopharmaceutical company developing novel therapies for invasive fungal infections, particularly in immunocompromised patients with limited treatment options. Direct antifungal-focused peer with similar unmet-need positioning.
  • Basilea Pharmaceutica: Swiss biopharmaceutical company with a commercialized antifungal franchise (Cresemba) and a pipeline in serious bacterial and fungal infections. Comparable as a focused anti-infective specialist with both development and commercial-stage assets.
  • Melinta Therapeutics: Commercial-stage anti-infective company with marketed antibiotics for serious and life-threatening infections. Comparable as a focused infectious disease company addressing hospitalized and immunocompromised patient populations.
  • Paratek Pharmaceuticals: Commercial-stage biopharmaceutical company developing and commercializing antibiotics for serious community-acquired infections. Comparable as an infectious disease-focused specialty company with similar development and commercialization dynamics.
  • Nabriva Therapeutics: Biopharmaceutical company developing anti-infective agents for serious and difficult-to-treat infections. Comparable as a development-stage anti-infective specialist addressing similar hospital and immunocompromised patient use cases.
  • Viamet Pharmaceuticals: Clinical-stage biopharmaceutical company developing novel antifungal agents using metalloenzyme inhibitors. Comparable as a development-stage antifungal specialist targeting invasive fungal infections.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Amplyx Pharmaceuticals social profiles

Digital presence

Amplyx Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amplyx Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Amplyx Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amplyx Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amplyx Pharmaceuticals

What does Amplyx Pharmaceuticals do?

Amplyx Pharmaceuticals develops innovative small-molecule therapies for debilitating and life-threatening diseases, with a primary focus on treating invasive fungal infections in patients with compromised immune systems. The company operates as a clinical-stage biopharmaceutical firm advancing novel antifungal drug candidates through preclinical and clinical development.

When was Amplyx Pharmaceuticals founded?

Amplyx Pharmaceuticals was founded in 2006. It employs 11 to 50 people.

Where is Amplyx Pharmaceuticals based?

Amplyx Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

Who are Amplyx Pharmaceuticals's main competitors?

Broad incumbents on record are Pfizer and Astellas Pharma. Direct peers are Cidara Therapeutics, Scynexis, F2G, Basilea Pharmaceutica, Melinta Therapeutics, Paratek Pharmaceuticals, Nabriva Therapeutics and Viamet Pharmaceuticals.

Does Amplyx Pharmaceuticals have an API?

No public API is recorded for Amplyx Pharmaceuticals.

What industry is Amplyx Pharmaceuticals in?

Amplyx Pharmaceuticals's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchAmlyx Pharmaceuticals sets IPO terms, as the company could be valued at up to $1.1 billionAmlyx Pharmaceuticals set IPO terms, offering 8.75 million shares at $18–$20 each to raise up to $175 million. The Nasdaq listing could value the company at up to $1.1 billion. The company reported a net loss of $59.6 million on revenue of $285,000 for the nine months ended Sept. 30.YahooPfizer buys Amplyx to expand drug-resistant treatment portfolioPfizer acquired privately-held Amplyx Pharmaceuticals, which is developing fosmanogepix, a new antifungal treatment for drug-resistant superbugs in immunocompromised patients. The drug would be the first new class of antifungals in 20 years, addressing a growing threat that could kill 10 million people annually by 2050.BenzingaThe Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping - iShThis article is a biotech market roundup detailing multiple corporate developments, including Roche's FDA panel vote supporting Tecentriq approval, Pfizer's acquisition of Amplyx Pharmaceuticals, and Protalix receiving a complete response letter for its Fabry disease treatment. It also reports on earnings results showing declines for Sanofi and Amgen, alongside various regulatory updates and financing activities across the sector.Business Wire BlogPfizer Acquires Amplyx PharmaceuticalsPfizer Inc. has acquired Amplyx Pharmaceuticals, a private biotechnology company, to expand its anti-infectives pipeline with the addition of Fosmanogepix (APX001), a novel antifungal candidate currently in Phase 2 clinical trials. This acquisition allows Pfizer to secure ownership of Amplyx's early-stage assets and advance its expertise in treating invasive fungal infections, building on an initial equity investment made in 2019. Financial terms of the deal were not disclosed.PR NewswireAmplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual MeetingAmplyx Pharmaceuticals announced that clinical and preclinical data for its Phase 2 program MAU868 will be presented at the 62nd American Society of Hematology Annual Meeting, taking place virtually December 5-8, 2020. The presentations include preclinical characterization data and first-in-human study results for MAU868, a novel neutralizing antibody targeting BK virus that is currently being evaluated in a multicenter Phase 2 clinical trial for kidney transplant recipients at centers in the US and Canada. There are currently no approved treatments for the conditions MAU868 targets, which include BKV-associated renal nephropathy and hemorrhagic cystitis.PR NewswireAmplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific ConferencesAmplyx Pharmaceuticals, a clinical-stage biopharmaceutical company based in San Diego, announced it will present new clinical and preclinical data for its two lead drug programs at IDWeek 2020 and ASN Kidney Week 2020, both being held virtually. The data includes positive Phase 2 results for fosmanogepix showing an 80% treatment success rate in candidemia patients, as well as first-in-human data for MAU868, a novel anti-BK virus antibody. Both drugs are in Phase 2 development for patients with compromised immune systems, with fosmanogepix having received Fast Track and Orphan Drug designations from the US FDA for multiple indications.PR NewswireAmplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant RecipientsAmplyx Pharmaceuticals has dosed the first patient in a Phase 2 clinical trial evaluating MAU868, a novel human monoclonal antibody, for the treatment of BK viremia in kidney transplant recipients. The trial is a multicenter, randomized, double-blind, placebo-controlled study being conducted at centers in the US and Canada. There are currently no approved treatments for BKV, which can cause transplanted kidney loss in immunocompromised patients, making this a first-in-class therapeutic development.PR NewswireAmplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor ConferencesAmplyx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its president and CEO Ciara Kennedy will present a corporate overview at three upcoming investor conferences in August 2020: the BTIG Biotechnology Conference, the Wedbush PacGrow Healthcare Conference, and the Canaccord Genuity 40th Annual Growth Conference. The company is developing therapies for patients with compromised immune systems, including two lead products: fosmanogepix, a first-in-class antifungal, and MAU868, a novel monoclonal antibody targeting the BK virus. The announcement reflects routine investor relations activity typical for clinical-stage biotech companies seeking visibility among institutional investors.HubsAmplyx Pharmaceuticals’ Fosmanogepix Hits the Mark in Phase II Candida StudyAmplyx Pharmaceuticals reported Phase II data showing its drug fosmanogepix achieved an 80% treatment success rate in a Candida study. The drug was well-tolerated with no serious adverse events, and patients could transition from intravenous to oral treatment. Full results will be presented at an upcoming medical conference.PR NewswireAmplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal FosmanogepixAmplyx Pharmaceuticals announced positive topline data from its Phase 2 clinical trial of fosmanogepix, a broad-spectrum antifungal, as a first-line treatment for invasive fungal infections caused by Candida, meeting its primary efficacy endpoint with an 80% treatment success rate. The drug was well tolerated with no treatment-related serious adverse events or discontinuations, and demonstrated potent activity against all Candida isolates including strains resistant to existing antifungal agents. The company plans to advance fosmanogepix toward registration for invasive candidiasis while continuing Phase 2 trials for other invasive fungal infections including aspergillosis and drug-resistant Candida auris.